Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report

Abstract

A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.

Novel Therapeutics in the Treatment of Uterine Sarcoma

“…71 In another case report, the combination of lenvatinib, a tyrosine kinase inhibitor, and pembrolizumab, a PD-1 inhibitor, resulted in clinically significant disease regression. 72 In an analysis of 18 adenosarcoma tumors using targeted nextgeneration sequencing, the most common alterations were mutations of ATRX (17%) and TP53 (11%); low-level amplification of MYBL1 (50%), MDM2 (28%), and CDK4 (28%); and loss of CDKN2A (28%), RB1 (17%), and BAP1 (17%). 73 Components of the PI3K/AKT/PTEN pathway were altered in 72% of cases, including those with and without sarcomatous overgrowth.…”

A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma

“…Pembrolizumab, a monoclonal PD-1 antibody, and lenvatinib, a tyrosine kinase inhibitor, have been reported to have activity for endometrial cancer ( Fujiwara et al, 2022 ). Previous case reports have suggested Mullerian adenocarcinomas show clinical benefit in response to pembrolizumab and lenvatinib ( Alcindor et al, 2021 ). Pembrolizumab treatment has also demonstrated encouraging activity in soft tissue sarcomas ( Tawbi et al, 2017 ).…”